Comment on “Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC”

I am writing to express our appreciation for the article titled "Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study" by Nassar et al. 1 Nassar A.H. Kim S.Y. Aredo J.V. et al. Consolidation osimertinib versus durvalumab versus observation following concurrent chemoradiation in unresectable EGFR-mutant non-small-cell lung cancer: a multicenter retrospective cohort study. J Thorac Oncol. 2024; https://doi.org/10.1016/j.jtho.2024.01.012 Abstract Full Text Full Text PDF Scopus (3) Google Scholar The authors have meticulously conducted a retrospective cohort study across multiple centers, which offered a robust data set that consolidation with osimertinib is associated with a considerably longer real-world progression-free survival compared with durvalumab or observation alone is both compelling and timely. However, we have three concerns with this conclusion. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyJournal of Thoracic OncologyPreviewDurvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. Full-Text PDF